- Home
- ARCT vs CRGX Comparison
ARCT vs CRGX Comparison
Compare ARCT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- CRGX
- Stock Information
- Founded
- ARCT 2013
- CRGX 2021
- Country
- ARCT United States
- CRGX United States
- Employees
- ARCT N/A
- CRGX N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- ARCT Health Care
- CRGX
- Exchange
- ARCT Nasdaq
- CRGX Nasdaq
- Market Cap
- ARCT 298.3M
- CRGX 190.0M
- IPO Year
- ARCT N/A
- CRGX 2023
- Fundamental
- Price
- ARCT $13.78
- CRGX $4.59
- Analyst Decision
- ARCT Strong Buy
- CRGX Hold
- Analyst Count
- ARCT 8
- CRGX 7
- Target Price
- ARCT $52.83
- CRGX $5.33
- AVG Volume (30 Days)
- ARCT 474.9K
- CRGX 1.9M
- Earning Date
- ARCT 08-04-2025
- CRGX 08-11-2025
- Dividend Yield
- ARCT N/A
- CRGX N/A
- EPS Growth
- ARCT N/A
- CRGX N/A
- EPS
- ARCT N/A
- CRGX N/A
- Revenue
- ARCT $143,680,000.00
- CRGX N/A
- Revenue This Year
- ARCT N/A
- CRGX $57.81
- Revenue Next Year
- ARCT $34.79
- CRGX N/A
- P/E Ratio
- ARCT N/A
- CRGX N/A
- Revenue Growth
- ARCT 15.38
- CRGX N/A
- 52 Week Low
- ARCT $8.04
- CRGX $3.00
- 52 Week High
- ARCT $25.88
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- ARCT 54.34
- CRGX 61.56
- Support Level
- ARCT $13.10
- CRGX $4.32
- Resistance Level
- ARCT $15.20
- CRGX $4.63
- Average True Range (ATR)
- ARCT 1.02
- CRGX 0.16
- MACD
- ARCT 0.07
- CRGX 0.04
- Stochastic Oscillator
- ARCT 55.21
- CRGX 76.44
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.